ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
19
views
0
references
Top references
cited by
116
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,849
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Author(s):
Michael Untch
,
Sibylle Loibl
,
Joachim Bischoff
,
Holger Eidtmann
,
Manfred Kaufmann
,
Jens-Uwe Blohmer
,
Jörn Hilfrich
,
Dirk Strumberg
,
Peter A. Fasching
,
Rolf Kreienberg
,
Hans Tesch
,
Claus Hanusch
,
Bernd Gerber
,
Mahdi Rezai
,
Christian Jackisch
,
Jens Huober
,
Thorsten Kühn
,
Valentina Nekljudova
,
Gunter von Minckwitz
Publication date:
2012-02-01
Journal:
The Lancet Oncology
Publisher:
Elsevier BV
Read this article at
ScienceOpen
Publisher
PubMed
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Recursive Rule based Visual Categorization
Author and article information
Journal
DOI::
10.1016/S1470-2045(11)70397-7
PubMed ID::
22257523
License:
https://www.elsevier.com/tdm/userlicense/1.0/
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
1,849
Neoadjuvant chemotherapy of paclitaxel with or without Rad001: results of the non-responder part of the GEPARQUINTO study
Authors:
J Huober
,
C Hanusch
,
PA Fasching
Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial
Authors:
Malgorzata Banys-Paluchowski
,
Sibylle Loibl
,
Isabell Witzel
…
Bericht vom 5. GBG-Jahrestreffen 07.–08.03.2008
Authors:
Cristina Pirvulescu
,
Sibylle Loibl
,
Gunter von Minckwitz
See all similar
Cited by
115
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
Authors:
Javier Cortés
,
Patricia Galván
,
Begoña Bermejo
…
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Authors:
Jiani Wang
,
Binghe Xu
Towards personalized treatment for early stage HER2-positive breast cancer
Authors:
Kristina Goutsouliak
,
Jamunarani Veeraraghavan
,
Vidyalakshmi Sethunath
…
See all cited by
Version 1
- Current
Version 1